Drug Profile
EMX 001
Alternative Names: DengueTcP; DengueTcPTM; EMX-001; Flavivirus vaccine - Emergex Vaccines; naNO-Dengue; PepGNP-Dengue; Universal Flavivirus vaccineLatest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Emergex Vaccines
- Class Dengue vaccines; Peptide vaccines; Synthetic vaccines; Viral vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Dengue
- Discontinued Yellow fever; Zika virus infection
Most Recent Events
- 08 Mar 2024 Discontinued - Preclinical for Yellow fever (Prevention) in United Kingdom (Transdermal) (Emergex pipeline, March 2024)
- 08 Mar 2024 Discontinued - Preclinical for Zika virus infection (Prevention) in United Kingdom (Transdermal) (Emergex pipeline, March 2024)
- 16 Jan 2024 Emergex enters into collaboration agreement with DEKA Research and Development advancing Emergex’s novel T cell-priming immune candidates against infectious diseases